Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Schwartz

Pediatrics Olney, MD Medical Doctor

NPI 1083658991 CMS profile 49271

18111 Prince Philip Dr, #311, Olney, MD 20832

Open in the dashboard

General payments

$3,843

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Schwartz of Olney, MD is reported in the CMS Open Payments database as having received $3,843 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $994 31
2024 General $1,220 38
2023 General $424 22
2022 General $291 16
2021 General $422 22
2020 General $256 15
2019 General $236 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Schwartz
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Melissa Schwartz were reported at $994. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Melissa Schwartz Pediatrics median Middle half National median
2019 $236 $86 $31–$183 $163
2020 $256 $49 $22–$110 $114
2021 $422 $68 $27–$158 $132
2022 $291 $77 $30–$173 $149
2023 $424 $88 $33–$190 $160
2024 $1,220 $94 $34–$206 $164
2025 $994 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $530 9 payments
  2. Supernus Pharmaceuticals, Inc. $491 21 payments
  3. Corium, Inc. $294 11 payments
  4. kaleo, Inc. $275 15 payments
  5. Merck Sharp & Dohme Corporation $230 12 payments
  6. Ironshore Pharmaceuticals Inc. $224 11 payments
  7. Pfizer Inc. $188 8 payments
  8. Cranial Technologies, Inc $152 10 payments
  9. Averitas Pharma Inc. $152 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $148 8 payments
  11. Other $1,160 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,828 158 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Jornay PM $530 9 payments
  2. Qelbree $441 18 payments
  3. Azstarys $294 11 payments
  4. AUVI-Q $275 15 payments
  5. GARDASIL 9 $189 10 payments
  6. VAXELIS $156 8 payments
  7. Doc Band $152 10 payments
  8. Qutenza $152 1 payment
  9. VYVANSE $148 8 payments
  10. VAXNEUVANCE $139 7 payments
  11. Other $2,322 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record